Fasenra

Active Ingredient(s): Benralizumab
FDA Approved: * November 14, 2017
Pharm Company: * ASTRAZENECA AB
Category: Asthma

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Fasenra Overview

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody medication which is developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[2][3] Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.[4][5] It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe e...

Read more Fasenra Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Benralizumab

Recent Fasenra Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Benralizumab
  • Injection: 30mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Fasenra: (2 results)

Sorted by National Drug Code
  • 0310-1730 Fasenra 30 mg/ml Subcutaneous Injection, Solution by Astrazeneca Pharmaceuticals Lp
  • 0310-1830 Fasenra 30 mg/ml Subcutaneous Injection, Solution by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Benralizumab or a similar ingredient: (1 result)